BMRN Quote, Financials, Valuation and Earnings

Bristol-Myers Squibb has a net margin of 14.23% compared to Biomarin Pharmaceutical's net margin of 10.18%. Biomarin Pharmaceutical's return on equity of 6.29% beat Bristol-Myers Squibb's return on equity of -33.18%.

Biomarin Pharmaceutical has a consensus price target of $98.08, signalling upside risk potential of 48%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $60.91 which suggests that it could grow by 5.78%. Given that Biomarin Pharmaceutical has higher upside potential than Bristol-Myers Squibb, analysts believe Biomarin Pharmaceutical is more attractive than Bristol-Myers Squibb.

Biomarin Pharmaceutical has a beta of 0.295, which suggesting that the stock is 70.544% less volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.454, suggesting its less volatile than the S&P 500 by 54.628%.

Biomarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol-Myers Squibb offers a yield of 4.17% to investors and pays a quarterly dividend of $0.60 per share. Biomarin Pharmaceutical pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out 59.12% of its earnings as a dividend. Bristol-Myers Squibb's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biomarin Pharmaceutical quarterly revenues are $745.7M, which are smaller than Bristol-Myers Squibb quarterly revenues of $11.9B. Biomarin Pharmaceutical's net income of $106.1M is lower than Bristol-Myers Squibb's net income of $1.2B. Notably, Biomarin Pharmaceutical's price-to-earnings ratio is 39.68x while Bristol-Myers Squibb's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomarin Pharmaceutical is 4.73x versus 2.46x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 14.23% compared to Biomarin Pharmaceutical's net margin of 18.95%. Biomarin Pharmaceutical's return on equity of 6.29% beat Merck &'s return on equity of 29.26%.

Biomarin Pharmaceutical has a consensus price target of $98.08, signalling upside risk potential of 48%. On the other hand Merck & has an analysts' consensus of $128.73 which suggests that it could grow by 29.54%. Given that Biomarin Pharmaceutical has higher upside potential than Merck &, analysts believe Biomarin Pharmaceutical is more attractive than Merck &.

Biomarin Pharmaceutical has a beta of 0.295, which suggesting that the stock is 70.544% less volatile than S&P 500. In comparison Merck & has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.746%.

Biomarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.14% to investors and pays a quarterly dividend of $0.81 per share. Biomarin Pharmaceutical pays -- of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend.

Biomarin Pharmaceutical quarterly revenues are $745.7M, which are smaller than Merck & quarterly revenues of $16.7B. Biomarin Pharmaceutical's net income of $106.1M is lower than Merck &'s net income of $3.2B. Notably, Biomarin Pharmaceutical's price-to-earnings ratio is 39.68x while Merck &'s PE ratio is 20.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomarin Pharmaceutical is 4.73x versus 4.00x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 14.23% compared to Biomarin Pharmaceutical's net margin of 0.7%. Biomarin Pharmaceutical's return on equity of 6.29% beat Moderna's return on equity of -17.44%.

Biomarin Pharmaceutical has a consensus price target of $98.08, signalling upside risk potential of 48%. On the other hand Moderna has an analysts' consensus of $127.09 which suggests that it could grow by 87.39%. Given that Moderna has higher upside potential than Biomarin Pharmaceutical, analysts believe Moderna is more attractive than Biomarin Pharmaceutical.

Biomarin Pharmaceutical has a beta of 0.295, which suggesting that the stock is 70.544% less volatile than S&P 500. In comparison Moderna has a beta of 1.582, suggesting its more volatile than the S&P 500 by 58.238%.

Biomarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomarin Pharmaceutical pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Biomarin Pharmaceutical quarterly revenues are $745.7M, which are smaller than Moderna quarterly revenues of $1.9B. Biomarin Pharmaceutical's net income of $106.1M is higher than Moderna's net income of $13M. Notably, Biomarin Pharmaceutical's price-to-earnings ratio is 39.68x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomarin Pharmaceutical is 4.73x versus 3.03x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 14.23% compared to Biomarin Pharmaceutical's net margin of 25.23%. Biomarin Pharmaceutical's return on equity of 6.29% beat Pfizer's return on equity of 4.63%.

Biomarin Pharmaceutical has a consensus price target of $98.08, signalling upside risk potential of 48%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.29%. Given that Biomarin Pharmaceutical has higher upside potential than Pfizer, analysts believe Biomarin Pharmaceutical is more attractive than Pfizer.

Biomarin Pharmaceutical has a beta of 0.295, which suggesting that the stock is 70.544% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Biomarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.29% to investors and pays a quarterly dividend of $0.42 per share. Biomarin Pharmaceutical pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Biomarin Pharmaceutical quarterly revenues are $745.7M, which are smaller than Pfizer quarterly revenues of $17.7B. Biomarin Pharmaceutical's net income of $106.1M is lower than Pfizer's net income of $4.5B. Notably, Biomarin Pharmaceutical's price-to-earnings ratio is 39.68x while Pfizer's PE ratio is 36.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomarin Pharmaceutical is 4.73x versus 2.56x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.